In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts.

"Declarations Competing Interest M.T.L is a Founder of, and an uncompensated Limited Partner in StemMed Ltd., as well as an uncompensated a Manager in, StemMed Holdings L.L.C., its General Partner. He is a Co-founder of, and equity stake holder in, Tvardi Therapeutics Inc., a Houston based pharmaceutical development company L.D. is a compensated employee of StemMed Ltd. Selected BCM PDX models described herein are exclusively licensed to StemMed Ltd. resulting in royalties to M.T.L. and L.D. M.T.L is a member of the editorial board for the Journal of Mammary Gland Biology and Neoplasia. Competing Interest M.T.L is a Founder of, and an uncompensated Limited Partner in StemMed Ltd., as well as an uncompensated a Manager in, StemMed Holdings L.L.C., its General Partner. He is a Co-founder of, and equity stake holder in, Tvardi Therapeutics Inc., a Houston based pharmaceutical development company L.D. is a compensated employee of StemMed Ltd. Selected BCM PDX models described herein are exclusively licensed to StemMed Ltd. resulting in royalties to M.T.L. and L.D. M.T.L is a member of the editorial board for the Journal of Mammary Gland Biology and Neoplasia."

"Funding This work was supported, in part, by a P30 Cancer Center Support Grant CA125123 (To C. Kent Osborne), a U54 PDXNet PDX Development and Trials Center grant (NCI U54 CA224076) (to M.T.L.), a U24 Co-clinical Imaging Research Resource Program grant (NCI U24 CA226110) (to M.T.L.), an RO1 grant (CA224867 to M.T.L.), and a Core Facility Support Grant from the Cancer Research and Prevention Initiative of Texas RP170691 (to M.T.L.)."